155 related articles for article (PubMed ID: 16986263)
1. Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design.
Kansal AR; Trimmer J
Syst Biol (Stevenage); 2005 Dec; 152(4):214-20. PubMed ID: 16986263
[TBL] [Abstract][Full Text] [Related]
2. Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development.
Krishna R; Schaefer HG; Bjerrum OJ
Eur J Pharm Sci; 2007 May; 31(1):62-7. PubMed ID: 17408933
[TBL] [Abstract][Full Text] [Related]
3. Extrapolation of preclinical data into clinical reality translational science.
Singer T
Ernst Schering Res Found Workshop; 2007; (59):1-5. PubMed ID: 17117711
[TBL] [Abstract][Full Text] [Related]
4. Predictive biosimulation and virtual patients in pharmaceutical R and D.
Bangs A
Stud Health Technol Inform; 2005; 111():37-42. PubMed ID: 15718695
[TBL] [Abstract][Full Text] [Related]
5. Biosimulation software is changing research.
Ho RL; Bartsell LT
Biotechnol Annu Rev; 2004; 10():297-302. PubMed ID: 15504712
[TBL] [Abstract][Full Text] [Related]
6. In silico prediction of clinical efficacy.
Michelson S; Sehgal A; Friedrich C
Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
[TBL] [Abstract][Full Text] [Related]
7. Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline.
Menshykau D
Drug Discov Today; 2017 Nov; 22(11):1598-1603. PubMed ID: 28545837
[TBL] [Abstract][Full Text] [Related]
8. Failure and success in modern drug discovery: guiding principles in the establishment of high probability of success drug discovery organizations.
Rishton GM
Med Chem; 2005 Sep; 1(5):519-27. PubMed ID: 16787336
[TBL] [Abstract][Full Text] [Related]
9. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
Cavagnaro J; Silva Lima B
Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
11. Identification and evaluation of molecular properties related to preclinical optimization and clinical fate.
Blake JF
Med Chem; 2005 Nov; 1(6):649-55. PubMed ID: 16787349
[TBL] [Abstract][Full Text] [Related]
12. Assessing the impact of predictive biosimulation on drug discovery and development.
Michelson S
J Bioinform Comput Biol; 2003 Apr; 1(1):169-77. PubMed ID: 15290786
[TBL] [Abstract][Full Text] [Related]
13. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
14. Translational medicine 2006.
Persiani S
IDrugs; 2006 Apr; 9(4):253-5. PubMed ID: 16596476
[No Abstract] [Full Text] [Related]
15. Stroke drug development: usually, but not always, animal models.
Donnan GA; Davis SM
Stroke; 2005 Oct; 36(10):2326. PubMed ID: 16141427
[No Abstract] [Full Text] [Related]
16. Use of animal models has not contributed to development of acute stroke therapies: pro.
Kaste M
Stroke; 2005 Oct; 36(10):2323-4. PubMed ID: 16141431
[No Abstract] [Full Text] [Related]
17. Use of animal models has not contributed to development of acute stroke therapies: con.
Fisher M; Tatlisumak T
Stroke; 2005 Oct; 36(10):2324-5. PubMed ID: 16141429
[No Abstract] [Full Text] [Related]
18. Approaches for predicting human pharmacokinetics using interspecies pharmacokinetic scaling.
Kang HE; Lee MG
Arch Pharm Res; 2011 Nov; 34(11):1779-88. PubMed ID: 22139680
[TBL] [Abstract][Full Text] [Related]
19. Microfluidics for drug discovery and development: from target selection to product lifecycle management.
Kang L; Chung BG; Langer R; Khademhosseini A
Drug Discov Today; 2008 Jan; 13(1-2):1-13. PubMed ID: 18190858
[TBL] [Abstract][Full Text] [Related]
20. Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop.
Bai JP; Bell R; Buckman S; Burckart GJ; Eichler HG; Fang KC; Goodsaid FM; Jusko WJ; Lesko LL; Meibohm B; Patterson SD; Puig O; Smerage JB; Snider BJ; Wagner JA; Wang J; Walton MK; Weiner R
AAPS J; 2011 Jun; 13(2):274-83. PubMed ID: 21448748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
